M. Day, P.A. Olson, J. Platzer, J. Striessnig i inni. Stimulation of 5-HT(2) receptors in prefrontal pyramidal neurons inhibits Ca(v)1.2 L type Ca(2+) currents via a PLCbeta/IP3/calcineurin signaling cascade. „J Neurophysiol”. 87 (5), s. 2490-2504, 2002. DOI: 10.1152/jn.00843.2001. PMID: 11976386.
N.H. Jensen, T.I. Cremers, F. Sotty. Therapeutic potential of 5-HT2C receptor ligands. „ScientificWorldJournal”. 10, s. 1870-1885, 2010. DOI: 10.1100/tsw.2010.180. PMID: 20852829.
A. Serretti, P. Artioli, D. De Ronchi. The 5-HT2C receptor as a target for mood disorders. „Expert Opin Ther Targets”. 8 (1), s. 15-23, 2004. DOI: 10.1517/14728222.8.1.15. PMID: 14996615.
M.J. Millan, M. Brocco, A. Gobert, A. Dekeyne. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. „Psychopharmacology (Berl)”. 177 (4), s. 448-458, 2005. DOI: 10.1007/s00213-004-1962-z. PMID: 15289999.
S.M. Stahl. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. „Int J Neuropsychopharmacol”. 10 (5), s. 575-578, 2007. DOI: 10.1017/S1461145707008000. PMID: 17681087.
W.J. Thomsen, A.J. Grottick, F. Menzaghi, H. Reyes-Saldana i inni. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. „J Pharmacol Exp Ther”. 325 (2), s. 577-587, 2008. DOI: 10.1124/jpet.107.133348. PMID: 18252809.
J.A. Siuciak, D.S. Chapin, S.A. McCarthy, V. Guanowsky i inni. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. „Neuropharmacology”. 52 (2), s. 279-290, 2007. DOI: 10.1016/j.neuropharm.2006.07.024. PMID: 16949622.
J. Dunlop, S.W. Watts, J.E. Barrett, J. Coupet i inni. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. „J Pharmacol Exp Ther”. 337 (3), s. 673-680, 2011. DOI: 10.1124/jpet.111.179572. PMID: 21402690.
S. Rosenzweig-Lipson, A. Sabb, G. Stack, P. Mitchell i inni. Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. „Psychopharmacology”. 192 (2), s. 159-170, 2007. DOI: 10.1007/s00213-007-0710-6. PMID: 17297636.
W.K. Kroeze, S.J. Hufeisen, B.A. Popadak, S.M. Renock i inni. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. „Neuropsychopharmacology”. 28 (3), s. 519-526, 2003. DOI: 10.1038/sj.npp.1300027. PMID: 12629531.
A. Dekeyne, C. Mannoury la Cour, A. Gobert, M. Brocco i inni. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.. „Psychopharmacology”. 199 (4), s. 549-568, 2008. DOI: 10.1007/s00213-008-1177-9. PMID: 18523738.
A.R. Knight, A. Misra, K. Quirk, K. Benwell i inni. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. „Naunyn Schmiedebergs Arch Pharmacol”. 370 (2), s. 114-123, 2004. DOI: 10.1007/s00210-004-0951-4. PMID: 15322733.
P.R. Buckland, B. Hoogendoorn, C.A. Guy, S.K. Smith i inni. Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. „Am J Psychiatry”. 162 (3), s. 613-615, 2005. DOI: 10.1176/appi.ajp.162.3.613. PMID: 15741483.
P.J. Conn, E. Sanders-Bush, BJ. Hoffman, P.R. Hartig. A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover. „Proc Natl Acad Sci U S A”. 83 (11), s. 4086-4088, 1986. PMID: 2940597.
M. Day, P.A. Olson, J. Platzer, J. Striessnig i inni. Stimulation of 5-HT(2) receptors in prefrontal pyramidal neurons inhibits Ca(v)1.2 L type Ca(2+) currents via a PLCbeta/IP3/calcineurin signaling cascade. „J Neurophysiol”. 87 (5), s. 2490-2504, 2002. DOI: 10.1152/jn.00843.2001. PMID: 11976386.
N.H. Jensen, T.I. Cremers, F. Sotty. Therapeutic potential of 5-HT2C receptor ligands. „ScientificWorldJournal”. 10, s. 1870-1885, 2010. DOI: 10.1100/tsw.2010.180. PMID: 20852829.
J.R. Martin, M. Bös, F. Jenck, J. Moreau i inni. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. „J Pharmacol Exp Ther”. 286 (2), s. 913-924, 1998. PMID: 9694950.
A. Serretti, P. Artioli, D. De Ronchi. The 5-HT2C receptor as a target for mood disorders. „Expert Opin Ther Targets”. 8 (1), s. 15-23, 2004. DOI: 10.1517/14728222.8.1.15. PMID: 14996615.
Y.G. Ni, R. Miledi. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). „Proc Natl Acad Sci U S A”. 94 (5), s. 2036-2040, 1997. PMID: 9050900.
M.J. Millan, M. Brocco, A. Gobert, A. Dekeyne. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. „Psychopharmacology (Berl)”. 177 (4), s. 448-458, 2005. DOI: 10.1007/s00213-004-1962-z. PMID: 15289999.
S.M. Stahl. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. „Int J Neuropsychopharmacol”. 10 (5), s. 575-578, 2007. DOI: 10.1017/S1461145707008000. PMID: 17681087.
W.J. Thomsen, A.J. Grottick, F. Menzaghi, H. Reyes-Saldana i inni. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. „J Pharmacol Exp Ther”. 325 (2), s. 577-587, 2008. DOI: 10.1124/jpet.107.133348. PMID: 18252809.
J.A. Siuciak, D.S. Chapin, S.A. McCarthy, V. Guanowsky i inni. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. „Neuropharmacology”. 52 (2), s. 279-290, 2007. DOI: 10.1016/j.neuropharm.2006.07.024. PMID: 16949622.
J. Dunlop, S.W. Watts, J.E. Barrett, J. Coupet i inni. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. „J Pharmacol Exp Ther”. 337 (3), s. 673-680, 2011. DOI: 10.1124/jpet.111.179572. PMID: 21402690.
S. Rosenzweig-Lipson, A. Sabb, G. Stack, P. Mitchell i inni. Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. „Psychopharmacology”. 192 (2), s. 159-170, 2007. DOI: 10.1007/s00213-007-0710-6. PMID: 17297636.
A. Hameg, F. Bayle, P. Nuss, P. Dupuis i inni. Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. „Biochem Pharmacol”. 65 (3), s. 435-440, 2003. PMID: 12527336.
W.K. Kroeze, S.J. Hufeisen, B.A. Popadak, S.M. Renock i inni. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. „Neuropsychopharmacology”. 28 (3), s. 519-526, 2003. DOI: 10.1038/sj.npp.1300027. PMID: 12629531.
A. Dekeyne, C. Mannoury la Cour, A. Gobert, M. Brocco i inni. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.. „Psychopharmacology”. 199 (4), s. 549-568, 2008. DOI: 10.1007/s00213-008-1177-9. PMID: 18523738.
G.A. Kennett, M.D. Wood, F. Bright, J. Cilia i inni. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. „Br J Pharmacol”. 117 (3), s. 427-434, 1996. PMID: 8821530.
A.R. Knight, A. Misra, K. Quirk, K. Benwell i inni. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. „Naunyn Schmiedebergs Arch Pharmacol”. 370 (2), s. 114-123, 2004. DOI: 10.1007/s00210-004-0951-4. PMID: 15322733.
P.R. Buckland, B. Hoogendoorn, C.A. Guy, S.K. Smith i inni. Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. „Am J Psychiatry”. 162 (3), s. 613-615, 2005. DOI: 10.1176/appi.ajp.162.3.613. PMID: 15741483.
